Immunogen Antibody Conjugate Patent Survives IPR

11.02.15 Posted in PTAB by

Immunogen’s US Patent 8,337,856, which claims antibody-toxin immunogates for the treatment of cancer, survives an IPR challenge in a final written decision by the PTAB. In an unpredictable art, the Board finds that general statements in the prior art giving hints of future research were insufficient to provide a reasonable expectation of success.

Apotex loses IPR on Prodrug Obviousness (Institution Denied)

06.29.15 Posted in PTAB by

Petitioner Apotex asserted that claims directed to fosaprepitant were obvious, but the PTAB finds that there was no valid lead compound, so the patent is not obvious.

Stay In Touch!
Subscribe to our Newsletter!

Enter your email address to subscribe to this blog and receive notifications of new posts by email.